Aevitas Therapeutics

Aevitas Therapeutics is a biopharmaceutical company focused on advancing gene therapy for short-form human H factor (sFH) to restore complement regulation in dry age-related macular degeneration (Dry AMD), atypical hemolytic uremic syndrome (aHUS), and other diseases characterized by complement dysregulation. Our sFH platform is based on an engineered, functional short-form H factor, whose transgene can be cloned into adeno-associated virus (AAV) for delivery via gene therapy.